Note 2 - Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2019

Notes Tables

Disaggregation of Revenue [Table Text Block]

	Year Ended December 31, 2019
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
Device Segment:
AXP	$	7,313,000	$	209,000			$	7,522,000
BioArchive		1,472,000		1,438,000				2,910,000
Manual Disposables		909,000		--				909,000
CAR-TXpress		1,457,000		13,000	$	95,000		1,565,000
Other		--		--		51,000		51,000
Total Device Segment		11,151,000		1,660,000		146,000		12,957,000
Clinical Development Segment:
Disposables		68,000		--		--		68,000
Other		--		22,000		--		22,000
Total Clinical Development		68,000		22,000		--		90,000
Total	$	11,219,000	$	1,682,000	$	146,000	$	13,047,000

	Year Ended December 31, 2018
	Device Revenue		Service Revenue		Other Revenue		Total Revenue
Device Segment:
AXP	$	4,131,000	$	262,000	$	--	$	4,393,000
BioArchive		1,792,000		1,306,000		--		3,098,000
Manual Disposables		976,000		--		--		976,000
CAR-TXpress		907,000		--		--		907,000
Other		--		--		95,000		95,000
Total Device Segment		7,806,000		1,568,000		95,000		9,469,000
Clinical Development Segment:
Bone Marrow		--		135,000		--		135,000
Other		38,000		30,000		--		68,000
Total Clinical Development		38,000		165,000		--		203,000
Total	$	7,844,000	$	1,733,000	$	95,000	$	9,672,000

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

	2020		2021		2022		2023		2024 and beyond		Total
Service revenue	$	848,000	$	632,000	$	228,000	$	90,000	$	30,000	$	1,828,000
Clinical revenue		14,000		14,000	$	14,000		14,000		181,000		237,000
Exclusivity Fee		286,000		286,000		286,000		286,000		760,000		1,904,000
Total	$	1,148,000	$	932,000	$	528,000	$	390,000	$	971,000	$	3,969,000

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	Year Ended December 31,
	2019		2018
Common stock equivalents of convertible promissory note and accrued interest		6,683,646		4,840,556
Vested Series A warrants		40,441		40,441
Unvested Series A warrants (1)		69,853		69,853
Warrants – other		1,281,327		1,616,227
Stock options		291,807		302,364
Total		8,367,074		6,869,441